Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Upper Gastrointestinal Cancer and Reflux Disease

  • Kim, Jin-Jo (Division of Gastrointestinal Surgery, Department of Surgery, The Catholic University of Korea, Incheon St. Mary's Hospital)
  • Received : 2013.05.21
  • Accepted : 2013.06.07
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

There is a growing evidence that gastroesophageal reflux disease is related to several upper gastrointestinal cancers, mainly the esophageal adenocarcinoma and a certain type of gastric cardia adenocarcinoma. Currently, the incidence of gastroesophageal reflux disease is rapidly increasing in Korea. Therefore, there is a possibility of such increasing cancerous incidents, similar to the western worlds. In this article, the relationship between gastroesophageal reflux disease and several upper gastrointestinal cancers, the components of refluxate which has possible causal relationship with carcinogenesis, and the clinical implications of such relationship in the management of gastroesophageal reflux disease patients are discussed through the review of literature.

Keywords

References

  1. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831. https://doi.org/10.1056/NEJM199903183401101
  2. Thrift AP, Pandeya N, Whiteman DC. Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol 2012;2:11.
  3. Lundell LR. Etiology and risk factors for esophageal carcinoma. Dig Dis 2010;28:641-644. https://doi.org/10.1159/000320452
  4. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007;56:918-925. https://doi.org/10.1136/gut.2006.114504
  5. Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008;57:298-305. https://doi.org/10.1136/gut.2007.137364
  6. Horii T, Koike T, Abe Y, Kikuchi R, Unakami H, Iijima K, et al. Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan: evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol 2011;46:710-719. https://doi.org/10.3109/00365521.2011.565069
  7. Nunobe S, Nakanishi Y, Taniguchi H, Sasako M, Sano T, Kato H, et al. Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int 2007;57:315-321. https://doi.org/10.1111/j.1440-1827.2007.02102.x
  8. Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am 2009;18:469-485. https://doi.org/10.1016/j.soc.2009.03.005
  9. Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G, et al. Barrett's esophagus and esophageal cancer: an overview. Int J Oncol 2012;41:414-424.
  10. Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett's esophagus: a review of the literature. J Gastrointest Surg 2011;15:708-718. https://doi.org/10.1007/s11605-011-1485-y
  11. Kim KM, Cho YK, Bae SJ, Kim DS, Shim KN, Kim JH, et al. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study. J Gastroenterol Hepatol 2012;27:741-745. https://doi.org/10.1111/j.1440-1746.2011.06921.x
  12. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-735. https://doi.org/10.1111/j.1440-1746.2009.05824.x
  13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917. https://doi.org/10.1002/ijc.25516
  14. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252. https://doi.org/10.1056/NEJMra035010
  15. Fujiwara Y, Takahashi S, Arakawa T, Sollano JD, Zhu Q, Kachintorn U, et al; IGICS Study Group. A 2008 questionnairebased survey of gastroesophageal reflux disease and related diseases by physicians in East Asian countries. Digestion 2009;80:119-128. https://doi.org/10.1159/000226088
  16. Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013;108:200-207. https://doi.org/10.1038/ajg.2012.387
  17. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma--a population-based cohort study. Am J Gastroenterol 2006;101:1193-1199. https://doi.org/10.1111/j.1572-0241.2006.00550.x
  18. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-477. https://doi.org/10.1001/jama.1995.03530060048032
  19. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010;32:1222-1227. https://doi.org/10.1111/j.1365-2036.2010.04471.x
  20. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005;97:1471-1478.
  21. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33. https://doi.org/10.1053/gast.2002.30297
  22. Nason KS, Wichienkuer PP, Awais O, Schuchert MJ, Luketich JD, O'Rourke RW, et al. Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg 2011;146:851-858. https://doi.org/10.1001/archsurg.2011.174
  23. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004;20:637-643. https://doi.org/10.1111/j.1365-2036.2004.02127.x
  24. Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, et al; Australian Cancer Study. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010;139:73-83. https://doi.org/10.1053/j.gastro.2010.04.009
  25. Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Phila) 2008;1:308-311. https://doi.org/10.1158/1940-6207.CAPR-08-0170
  26. Islami F, Sheikhattari P, Ren JS, Kamangar F. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma-- a systematic review and meta-analysis. Ann Oncol 2011;22:754-760. https://doi.org/10.1093/annonc/mdq411
  27. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila) 2008;1:329-338. https://doi.org/10.1158/1940-6207.CAPR-08-0109
  28. 2010 Annual report of the Korea central cancer registry. Available at: http://www.ncc.re.kr/Accessed May 30, 2013.
  29. Asaka M, Kimura T, Kato M, Kudo M, Miki K, Ogoshi K, et al. Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer 1994;73:2691-2694. https://doi.org/10.1002/1097-0142(19940601)73:11<2691::AID-CNCR2820731107>3.0.CO;2-2
  30. Hansson LR, Engstrand L, Nyrén O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology 1995;109:885-888. https://doi.org/10.1016/0016-5085(95)90398-4
  31. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297-301.
  32. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789. https://doi.org/10.1056/NEJMoa001999
  33. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009;125:666-673. https://doi.org/10.1002/ijc.24290
  34. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-256.
  35. Kim JY, Lee HS, Kim N, Shin CM, Lee SH, Park YS, et al. Prevalence and clinicopathologic characteristics of gastric cardia cancer in South Korea. Helicobacter 2012;17:358-368. https://doi.org/10.1111/j.1523-5378.2012.00958.x
  36. Lee JY, Kim HY, Kim KH, Jang HJ, Kim JB, Lee JH, et al. No changing trends in incidence of gastric cardia cancer in Korea. J Korean Med Sci 2003;18:53-57.
  37. Kim JI, Kim SG, Kim N, Kim JG, Shin SJ, Kim SW, et al; Korean College of Helicobacter and Upper Gastrointestinal Research. Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol 2009;21:787-793. https://doi.org/10.1097/MEG.0b013e32830e285a
  38. Demicco EG, Farris AB 3rd, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinaltype vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 2011;24:1177-1190. https://doi.org/10.1038/modpathol.2011.77
  39. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991;101:1149-1158.
  40. Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 2001;15:269-276. https://doi.org/10.1046/j.1365-2036.2001.00939.x
  41. Orlando RC. Pathogenesis of reflux esophagitis and Barrett's esophagus. Med Clin North Am 2005;89:219-241. https://doi.org/10.1016/j.mcna.2004.08.006
  42. Falk GW, Jacobson BC, Riddell RH, Rubenstein JH, El-Zimaity H, Drewes AM, et al. Barrett's esophagus: prevalence-incidence and etiology-origins. Ann N Y Acad Sci 2011;1232:1-17. https://doi.org/10.1111/j.1749-6632.2011.06042.x
  43. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995;222:525-531. https://doi.org/10.1097/00000658-199522240-00010
  44. Kauer WK, Stein HJ. Emerging concepts of bile reflux in the constellation of gastroesophageal reflux disease. J Gastrointest Surg 2010;14 Suppl 1:S9-16. https://doi.org/10.1007/s11605-009-1014-4
  45. Bremner CG, Lynch VP, Ellis FH Jr. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970;68:209-216.
  46. Gillen P, Keeling P, Byrne PJ, West AB, Hennessy TP. Experimental columnar metaplasia in the canine oesophagus. Br J Surg 1988;75:113-115. https://doi.org/10.1002/bjs.1800750208
  47. Lillemoe KD, Johnson LF, Harmon JW. Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus. Gastroenterology 1983;85:621-628.
  48. Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GW, Mirvish SS, et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 1996;224:358-370. https://doi.org/10.1097/00000658-199609000-00012
  49. Cheng P, Li JS, Gong J, Zhang LF, Chen RZ. Effects of refluxate pH values on duodenogastroesophageal reflux-induced esophageal adenocarcinoma. World J Gastroenterol 2011;17:3060- 3065. https://doi.org/10.3748/wjg.v17.i25.3060
  50. Yamada T, Ishida Y, Nakamura Y, Shimada S. Bile-acidinduced calcium signaling in mouse esophageal epithelial cells. Biochem Biophys Res Commun 2011;414:789-794. https://doi.org/10.1016/j.bbrc.2011.10.004
  51. Zhang T, Zhang F, Han Y, Gu Z, Zhou Y, Cheng Q, et al. A rat surgical model of esophageal metaplasia and adenocarcinomainduced by mixed reflux of gastric acid and duodenal contents. Dig Dis Sci 2007;52:3202-3208. https://doi.org/10.1007/s10620-007-9774-8
  52. Fein M, Peters JH, Chandrasoma P, Ireland AP, Oberg S, Ritter MP, et al. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. J Gastrointest Surg 1998;2:260-268. https://doi.org/10.1016/S1091-255X(98)80021-8
  53. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-1199. https://doi.org/10.1053/gast.1996.v111.pm8898632
  54. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994;107:747-754. https://doi.org/10.1016/0016-5085(94)90123-6
  55. Waring JP, Legrand J, Chinichian A, Sanowski RA. Duodenogastric reflux in patients with Barrett's esophagus. Dig Dis Sci 1990;35:759-762. https://doi.org/10.1007/BF01540180
  56. Lirón R, Parrilla P, Martinez de Haro LF, Ortiz A, Robles R, Luján JA, et al. Quantification of duodenogastric reflux in Barrett's esophagus. Am J Gastroenterol 1997;92:32-36.
  57. Stein HJ, Feussner H, Kauer W, DeMeester TR, Siewert JR. Alkaline gastroesophageal reflux: assessment by ambulatory esophageal aspiration and pH monitoring. Am J Surg 1994;167:163-168. https://doi.org/10.1016/0002-9610(94)90068-X
  58. Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, Stein HJ, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997;122:874-881. https://doi.org/10.1016/S0039-6060(97)90327-5
  59. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP. Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg 1995;82:657-660. https://doi.org/10.1002/bjs.1800820528
  60. Stein HJ, Barlow AP, DeMeester TR, Hinder RA. Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg 1992;216:35-43. https://doi.org/10.1097/00000658-199207000-00006
  61. Hopwood D, Bateson MC, Milne G, Bouchier IA. Effects of bile acids and hydrogen ion on the fine structure of oesophageal epithelium. Gut 1981;22:306-311. https://doi.org/10.1136/gut.22.4.306
  62. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602. https://doi.org/10.1136/gut.44.5.598
  63. Bajpai M, Aviv H, Das KM. Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium. Mol Cytogenet 2012;5:43. https://doi.org/10.1186/1755-8166-5-43
  64. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331-2338. https://doi.org/10.1001/jama.285.18.2331
  65. Ye W, Chow WH, Lagergren J, Yin L, Nyrén O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001;121:1286-1293. https://doi.org/10.1053/gast.2001.29569
  66. DeMeester SR. Antireflux surgery and the risk of esophageal adenocarcinoma: an antithetical view of the data from sweden. Ann Surg 2013;257:583-585. https://doi.org/10.1097/SLA.0b013e3182895226
  67. Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA. Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg 2003;238:458-464.
  68. Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, De- Meester SR, Crookes PF, et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 2001;234:532-538. https://doi.org/10.1097/00000658-200110000-00012
  69. Vallböhmer D, DeMeester SR, Oh DS, Banki F, Kuramochi H, Shimizu D, et al. Antireflux surgery normalizes cyclooxygenase- 2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol 2006;101:1458-1466. https://doi.org/10.1111/j.1572-0241.2006.00601.x
  70. Oh DS, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg 2007;142:554-559. https://doi.org/10.1001/archsurg.142.6.554
  71. Martinez de Haro LF, Ortiz A, Parrilla P, Munitiz V, Martinez CM, Revilla B, et al. Long-term follow-up of malignancy biomarkers in patients with Barrett's esophagus undergoing medical or surgical treatment. Ann Surg 2012;255:916-921. https://doi.org/10.1097/SLA.0b013e31824e6c6a
  72. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599-1606. https://doi.org/10.1053/gast.2001.24840
  73. Tamhankar AP, Peters JH, Portale G, Hsieh CC, Hagen JA, Bremner CG, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004;8:890-897.
  74. Gutschow CA, Bludau M, Vallböhmer D, Schröder W, Bollschweiler E, Hölscher AH. NERD, GERD, and Barrett's esophagus: role of acid and non-acid reflux revisited with combined pH-impedance monitoring. Dig Dis Sci 2008;53:3076-3081. https://doi.org/10.1007/s10620-008-0270-6
  75. Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg 1998;2:333-341. https://doi.org/10.1016/S1091-255X(98)80072-3
  76. Lee SK, Kim EK. Laparoscopic Nissen fundoplication in Korean patients with gastroesophageal reflux disease. Yonsei Med J 2009;50:89-94. https://doi.org/10.3349/ymj.2009.50.1.89

Cited by

  1. Golgi Phosphoprotein 2 Down-regulates the Th1 Response in Human Gastric Cancer Cells by Suppressing IL-12A vol.14, pp.10, 2013, https://doi.org/10.7314/apjcp.2013.14.10.5747
  2. The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis vol.29, pp.3, 2013, https://doi.org/10.1007/s10654-014-9895-2
  3. Family History and Survival of Patients with Gastric Cancer: A Meta-Analysis vol.15, pp.8, 2013, https://doi.org/10.7314/apjcp.2014.15.8.3465
  4. Higher incidence of gastroesophageal reflux disease after gastric wedge resections of gastric submucosal tumors located close to the gastroesophageal junction vol.86, pp.6, 2014, https://doi.org/10.4174/astr.2014.86.6.289
  5. Benign Disease of the Stomach vol.15, pp.2, 2013, https://doi.org/10.5230/jgc.2015.15.2.75
  6. A Rare Disease of the Digestive Tract: Esophageal Melanosis vol.9, pp.2, 2016, https://doi.org/10.14740/gr670w
  7. Computed Tomographic Findings of Adenocarcinoma of the Esophagocardia Region in a Pekingese Dog with Brachycephalic Syndrome vol.34, pp.4, 2013, https://doi.org/10.17555/jvc.2017.08.34.4.295
  8. A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors vol.15, pp.3, 2013, https://doi.org/10.1080/17474124.2021.1845140